Stealth BioTherapeutics Announces Positive Vote from FDA Advisory Committee Meeting Supporting Potential Approval of Elamipretide for the Treatment of Barth Syndrome Press Release / October 11, 2024October 11, 2024
Stealth BioTherapeutics to Present at UBS Virtual Ophthalmology Day Press Release / September 27, 2024September 30, 2024
Stealth BioTherapeutics Presents New Bevemipretide (SBT-272) Data at Keystone Symposium Targeting Dry Age-Related Macular Degeneration Press Release / September 18, 2024September 19, 2024
Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences Press Release / September 12, 2024September 19, 2024
Stealth BioTherapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance to Develop Investigational Mitochondrial Therapeutic SBT-589 for Friedreich’s Ataxia Press Release / September 11, 2024September 19, 2024
Stealth BioTherapeutics Announces FDA Advisory Committee Meeting to Review Elamipretide for Barth Syndrome Treatment Press Release / September 9, 2024September 9, 2024
Stealth BioTherapeutics Completes Mid-Cycle Review Meeting on Elamipretide for the Treatment of Barth Syndrome Press Release / July 29, 2024July 29, 2024
Stealth BioTherapeutics Announces First Patient Enrolled in Global Phase 3 Clinical Program for Elamipretide in Patients with Dry Age-Related Macular Degeneration Uncategorized / June 5, 2024June 5, 2024
Stealth BioTherapeutics’ Barth Syndrome NDA Receives Priority Review Designation Press Release / May 7, 2024June 3, 2024
Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference Press Release / May 6, 2024June 3, 2024
